These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 18623377)

  • 1. High-dose therapy and autologous stem cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
    Gopal AK; Metcalfe TL; Gooley TA; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg L; Maloney DG; Press OW
    Cancer; 2008 Sep; 113(6):1344-50. PubMed ID: 18623377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma.
    Gerrie AS; Power MM; Shepherd JD; Savage KJ; Sehn LH; Connors JM
    Ann Oncol; 2014 Nov; 25(11):2218-2223. PubMed ID: 25149708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of high-dose therapy and autologous hematopoietic stem cell transplantation for non-Hodgkin's lymphoma in adults 60 years of age and older.
    Gopal AK; Gooley TA; Golden JB; Maloney DG; Bensinger WI; Petersdorf SH; Appelbaum FR; Press OW
    Bone Marrow Transplant; 2001 Mar; 27(6):593-9. PubMed ID: 11319588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.
    Perz JB; Giles C; Szydlo R; O'Shea D; Sanz J; Chaidos A; Wagner S; Davis J; Loaiza S; Marin D; Apperley J; Olavarria E; Rahemtulla A; Lampert I; Naresh K; Samson D; MacDonald D; Kanfer EJ
    Bone Marrow Transplant; 2007 Jan; 39(1):41-7. PubMed ID: 17115062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience.
    Viviani S; Di Nicola M; Bonfante V; Di Stasi A; Carlo-Stella C; Matteucci P; Magni M; Devizzi L; Valagussa P; Gianni AM
    Leuk Lymphoma; 2010 Jul; 51(7):1251-9. PubMed ID: 20528244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High dose therapy with autologous stem cell transplantation in patients with Hodgkin's lymphoma: long-term follow-up in patients treated in one center].
    Trnĕný M; Vacková B; Pytlík R; Cieslar P; Válková V; Gasová Z; Kobylka P; Trnková M; Krejcová H; Klener P
    Cas Lek Cesk; 2006; 145(1):19-24. PubMed ID: 16468237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
    Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
    Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose chemotherapy and autologous stem-cell transplantation in Korean patients with relapsed or refractory Hodgkin lymphoma.
    Park K; Yoon DH; Kim S; Park CS; Huh J; Lee SW; Suh C
    Int J Hematol; 2013 Feb; 97(2):256-62. PubMed ID: 23355263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1(1):CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involved field radiation therapy following high dose chemotherapy and autologous stem cell transplant benefits local control and survival in refractory or recurrent Hodgkin lymphoma.
    Biswas T; Culakova E; Friedberg JW; Kelly JL; Dhakal S; Liesveld J; Phillips GL; Constine LS
    Radiother Oncol; 2012 Jun; 103(3):367-72. PubMed ID: 22398312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
    Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
    Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Milgrom SA; Jauhari S; Plastaras JP; Nieto Y; Dabaja BS; Pinnix CC; Smith GL; Allen PK; Lukens JN; Maity A; Oki Y; Fanale MA; Nasta SD
    Cancer; 2017 Apr; 123(8):1363-1371. PubMed ID: 27984652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of conditioning regimen on outcome of 2-year disease-free survivors of autologous stem cell transplantation for Hodgkin lymphoma.
    William BM; Loberiza FR; Whalen V; Bierman PJ; Bociek RG; Vose JM; Armitage JO
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):417-23. PubMed ID: 23773453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma.
    Akhtar S; Rauf SM; Elhassan TA; Maghfoor I
    Ann Hematol; 2016 Sep; 95(9):1521-35. PubMed ID: 27376363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era.
    Varma G; Diefenbach C
    Semin Hematol; 2024 Aug; 61(4):253-262. PubMed ID: 39039012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High dose chemoradiotherapy with autologous hemotopoietic stem cell transplantation for treatment of patients with advanced Hodgkin's lymphoma: a report of 11 cases].
    Zhou SY; Shi YK; He XH; Han XH; Liu P; Yang JL; Zhou AP; Feng FY
    Ai Zheng; 2002 Apr; 21(4):405-8. PubMed ID: 12452021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma.
    Moskowitz CH; Matasar MJ; Zelenetz AD; Nimer SD; Gerecitano J; Hamlin P; Horwitz S; Moskowitz AJ; Noy A; Palomba L; Perales MA; Portlock C; Straus D; Maragulia JC; Schoder H; Yahalom J
    Blood; 2012 Feb; 119(7):1665-70. PubMed ID: 22184409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Shah GL; Yahalom J; Matasar MJ; Verwys SL; Goldman DA; Bantilan KS; Zhang Z; McCall SJ; Moskowitz AJ; Moskowitz CH
    Br J Haematol; 2016 Nov; 175(3):440-447. PubMed ID: 27377168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.